Dermatology company Galderma (SIX: GALD) on Monday revealed promising Phase III results from the READY-4 trial, demonstrating the long-term safety and efficacy of RelabotulinumtoxinA (Relfydess) for treating frown lines and crow's feet.

Data presented at the American Society for Dermatologic Surgery (ASDS) 2024 Annual Meeting indicates that repeated injections maintain efficacy and patient satisfaction across multiple treatments, with fewer than 20% of participants reporting mild to moderate treatment-related adverse events.

The READY-4 study, involving over 900 participants, confirmed that the safety profile aligns with earlier trials. Most participants maintained minimal to mild wrinkle severity after treatment, achieving high satisfaction rates (≥84%) within a month. Additional data from the broader READY clinical trial program shows that up to 39% of patients experience effects from day one, with about 75% sustaining improvements for six months.

RelabotulinumtoxinA, developed using PEARL Technology, is the first ready-to-use liquid neuromodulator designed for easy volumetric dosing. Following the successful completion of its European decentralised procedure in July 2024, Galderma is finalising national approvals across various markets and aims for a launch in the first half of 2025.

Galderma continues to expand its injectable aesthetics portfolio, reinforcing its leadership in the dermatology sector.